Houston startup advances in Chevron's unique business accelerator

scaling up

Currently, methane leak detection requires human evaluation. With this innovative new company's tech, this process can be automated. Photo via Getty Images

A Houston startup that is developing a technology to detect methane leaks has moved on to phase two in Chevron's unique business accelerator.

Aquanta Vision Technologies, a Houston-based climate-tech startup, was selected to participate in the scale-up phase of Chevron Studio, a Houston program that matches entrepreneurs with technologies to turn them into businesses. Aquanta's computer vision software completely automates the identification of methane in optical gas imaging, or OGI. The technology originated from Colorado State University and CSU STRATA Technology Transfer.

Babur Ozden, a tech startup entrepreneur, along with Marcus Martinez, the lead inventor and Dan Zimmerle, co-inventor and director of METEC at CSU Energy Institute, came up with the technology to identify the presence and motion of methane in live video streams. Currently, this process of identifying methane requires a human camera operator to interpret the images. This can often be unreliable in the collection of emissions data.

Babur Ozden is the founder of Aquanta Vision. Photo via LinkedIn

Aquanta’s technology requires no human intervention and is universally compatible with all OGI cameras. Currently, only about 10 percent of the 20.5 million surveys done worldwide use this type of technology as it is extremely expensive to produce. Ozden said he hopes Aquanta will change that model.

“What we are doing — we are democratizing this feature, this capability, independent of the camera make and model,” Ozden tells EnergyCapital.

Aquanta’s software will be downloadable from App stores to the technician’s computers or phones.

“Our goal is to eliminate the absolute reliance of human interpretation and to give operators a chance to make detections faster and more accurately,” Ozden says.

“Our ultimate ambition is to reduce our footprint.” he continues. “Companies like Chevron and other leading players in the oil and gas industry are becoming much more committed (to reducing emissions)."

Aquanta will now test its software under various scenarios and develop an early commercial version of the product. In the next and final phase of the program, the company will begin marketing the technology for commercial use.

The goal of Chevron Studio is to take innovative new technologies out of the labs at universities and to scale them up to commercial ventures. The company takes the intellectual property developed at these labs and provides a platform to match entrepreneurs with the technology. The program provides funding to take the technologies from the very beginning to pilot and field trials. The National Renewable Energy Laboratory, or NREL, manages Chevron Studio and works closely with the entrepreneurs to guide them through the program.

Gautam Phanse, the strategic relations manager for Chevron Technology Ventures says he was impressed with Ozden’s background as an entrepreneur and in the technology he brought to the table.

“We are looking at experienced entrepreneurs. People who can take an idea and stand on their own and develop it into a business,” he tells EnergyCapital.

Earlier this year, Phanse spoke to InnovationMap about Chevron Studio and its mission to match entrepreneurs with promising technologies coming out of universities and labs. He said the current focus areas for Chevron Studio are: carbon utilization, hydrogen and renewable energy, energy storage systems and solutions for circular economy.

------

This article originally ran on EnergyCapital.

From Your Site Articles
This week's roundup of Houston innovators includes Gautam Phanse of Chevron Technology Ventures, Dede Raad of Dress Up Buttercup, and Benjamin Foster of Nurseify. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from climatetech to health care — recently making headlines in Houston innovation.


Gautam Phanse, strategic relationship manager for Chevron Technology Ventures

Gautam Phanse of Chevron Technology Ventures answers questions about this unique program. Photo courtesy

Houston-based Chevron Technology Ventures has applications open for its second Chevron Studio cohort that matches entrepreneurs with promising technologies coming out of universities and labs. The overall goal of the studio — a collaboration between Chevron and the National Renewable Energy Laboratory, or NREL — is to scale up and commercialize early-stage technologies that have the potential to impact the future of energy.

"The goal of Chevron Studio is to scale up and commercialize technology developed in the Universities and National Labs. We curate the intellectual property developed at universities and national labs and provide a platform to match entrepreneurs with the IP," says Gautam Phanse, the strategic relationship manager for Chevron Technology Ventures. "The program provides seed funding and a pathway through incubation, pilot and field trials to scale up the technologies. The uniqueness of this program is its target and the breadth of its scope — all the way from incubation to field trials."

Phanse joins InnovationMap for a Q&A to explain more about the opportunity. Read more.

Dede Raad, founder of Dress Up Buttercup

Dede Raad of Dress Up Buttercup created a unique pitch series — completely fueled by her social media community — that gave a spotlight to eight businesses. Photo via dressupbuttercup.com

After growing her audience to over a million followers on Instagram, Houston fashion blogger Dede Raad felt the pressure to expand her business — but she didn't feel inspired by any particular line of business to grow into.

"In the blogging world, which I've been doing for about seven years, everyone's next step is to start a brand and to start something of their own," Raad, founder of Dress Up Buttercup, tells InnovationMap. "I just don't have anything in my heart that I was really passionate about. I know once you start something, you have to give it your all."

But what Raad realized — after a year of thinking about her next move and a chance viewing of Shark Tank — was that tons of business founders were passionate about their own brands, and there was an opportunity for Raad use her community to support them instead of coming up with something of her own. She launched "Build Up Buttercup," an initiative that featured small business pitches for a select group of investors. Read more.

Benjamin Foster, CEO and founder of Nurseify

In honor of Black History Month, Houstonian Benjamin Foster shares some of his lessons learned about navigating the business world as a Black founder. Photo courtesy

Last month was a time to reflect on Black history — as well as to look forward to the future of Black Americans. Benjamin Foster, a Houston entrepreneur, wrote a guest column about his experience as a Black founder.

"No matter how smart or hard working you are, it is impossible for a nonprofit owner, entrepreneur, or business owner to know everything about running and managing a business," he writes. "For me, I understood the health care industry and business management side, but I acknowledged that as a founder, it was okay to not know it all and to need the support of a village to get traction to keep moving forward." Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings